Nemvaleukin Alfa
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 2016 (NCT02799095)
Timeline
Indications
Mechanism of action
IL2RA agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095282 ↗
Also known as
- alks 4230
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05092360 | Phase 3 | Nov 30, 2021 | Alkermes, Merck |
| NCT04830124 | Phase 2 | May 27, 2021 | Alkermes |
| NCT04592653 | Phase 2 | Sep 30, 2020 | Alkermes |
| NCT04144517 | Phase 2 | Oct 31, 2019 | Alkermes, Immune Oncology Network |
| NCT03861793 | Phase 1 | Feb 26, 2019 | Alkermes |
| NCT02799095 | Phase 1 | Jul 1, 2016 | Alkermes |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alkermes | For profit | 6 | 6 | 3 | 2016 |
| Immune Oncology Network | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Merck | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1